Fatty Acid Modified Forms of Glucocorticoids

a technology of glucocorticoids and fatty acids, which is applied in the direction of steroid, medical preparations, organic chemistry, etc., can solve the problems of preventing the realization of the maximum pharmacologic value, preventing the effect of adsorption of adsorption, and causing the same side effects as swallowing drugs

Inactive Publication Date: 2008-09-11
SEPACOR INC
View PDF14 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The compounds demonstrate reduced systemic side effects and improved efficacy in treating bronchospasm, asthma, and inflammatory conditions, with extended duration of action and potential for once-a-day dosing, as shown in biological testing and rat paw edema models, while maintaining anti-inflammatory activity.

Problems solved by technology

Notwithstanding the sophistication of many formulations, many glucocorticoids exhibit significant side-effects that prevent realization of their maximum pharmacologic value.
These side-effects stem, in part, from the difficulty of effectively delivering the glucocorticoid drug to a target tissue without increasing systemic concentrations of the drug.
In the general patient population probably only 10% or so of the dose gets into the lungs due to improper use of the inhaler.
For early generation inhaled glucocorticoids, the swallowed drug leads to the same side effects seen with oral glucocorticoids.
Although newer glucocorticoids (e.g. budesonide, ciclesonide, triamcinolone and fluticasone) exhibit reduced systemic side effects from swallowed drug—being either poorly absorbed in the gut or subject to extensive inactivation in the liver—they nonetheless display systemic side effects as a result of absorption from the lung into the systemic circulation.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Fatty Acid Modified Forms of Glucocorticoids
  • Fatty Acid Modified Forms of Glucocorticoids
  • Fatty Acid Modified Forms of Glucocorticoids

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of the Docosahexaenoic Acid Ester of Budesonide

[0020]A solution of 1.0 gm (3×10−3 moles) of docosahexaenoic acid in methylene chloride (10 mL) was treated with thionyl chloride (0.357 gm, 3×10−3 moles) and two drops of DMF. This solution was heated at 30° C. for two hours. After cooling the solvent and any unreacted thionyl chloride were removed under vacuum. The residue was added dropwise to a solution of budesonide (1.0 gm, 2.3×10−3 moles) in pyridine (10 mL) with stirring and ice cooling. After the addition was complete the reaction mixture was stirred at room temperature for one hour. Water (50 mL) containing 85% phosphoric acid (5 mL) was added and the insoluble material was extracted into diethyl ether (50 mL). After discarding the aqueous phase, the ether solution was washed with water (50 mL) containing 85% phosphoric acid (5 mL). The ether solution was dried over magnesium sulfate, then filtered and stripped under vacuum. The residue was purified by chromatography...

example 2

Synthesis of the Docosapentaenoic Acid Ester of Budesonide

[0021]A solution of 1.0 gm (3×10−3 moles) of docosapentaenoic acid in methylene chloride (10 mL) was treated with thionyl chloride (0.357 gm, 3×10−3 moles) and two drops of DMF. This solution was heated at 30° C. for two hours. After cooling the solvent and any unreacted thionyl chloride were removed under vacuum. The residue was added dropwise to a solution of budesonide (1.0 gm, 2.3×10−3 moles) in pyridine (10 mL) with stirring and ice cooling. After the addition was complete the reaction mixture was stirred at room temperature for one hour. Water (50 mL) containing 85% phosphoric acid (5 mL) was added and the insoluble material was extracted into diethyl ether (50 mL). After discarding the aqueous phase, the ether solution was washed with water (50 mL) containing 85% phosphoric acid (5 mL). The ether solution was dried over magnesium sulfate, then filtered and stripped under vacuum. The residue was purified by chromatograp...

example 3

Synthesis of the Eicosapentaenoic Acid Ester of Budesonide

[0022]A solution of 0.90 gm (3×10−3 moles) of eicosapentaenoic acid in methylene chloride (10 mL) was treated with thionyl chloride (0.357 gm, 3×10−3 moles) and two drops of DMF. This solution was heated at 30° C. for two hours. After cooling the solvent and any unreacted thionyl chloride were removed under vacuum. The residue was added dropwise to a solution of budesonide (1.0 gm, 2.3×10−3 moles) in pyridine (10 mL) with stirring and ice cooling. After the addition was complete the reaction mixture was stirred at room temperature for one hour. Water (50 mL) containing 85% phosphoric acid (5 mL) was added and the insoluble material was extracted into diethyl ether (50 mL). After discarding the aqueous phase, the ether solution was washed with water (50 mL) containing 85% phosphoric acid (5 mL). The ether solution was dried over magnesium sulfate, then filtered and stripped under vacuum. The residue was purified by chromatogra...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compounds are disclosed of the formulain which R3 is C8 to C24 hydrocarbon or the residue of misoprostol. The compounds are useful for treating rhinitis and asthma, particularly by inhalation, and for treating inflammation, particularly by local or topical administration.

Description

CROSS REFERENCE TO RELATED APPLICATIONS[0001]This application is a continuation of U.S. application Ser. No. 10 / 681,614, filed Oct. 8, 2003, which claims priority from U.S. provisional application 60 / 416,840, filed Oct. 8, 2002, the entire disclosure of which are incorporated herein by reference.FIELD OF THE INVENTION[0002]The invention relates to antiasthmatic ester derivatives of glucocorticoids.BACKGROUND OF THE INVENTION[0003]Glucocorticoids, in topical, oral and inhaled formulations, are useful for their anti-inflammatory and immunosuppressive activities. Notwithstanding the sophistication of many formulations, many glucocorticoids exhibit significant side-effects that prevent realization of their maximum pharmacologic value. These side-effects stem, in part, from the difficulty of effectively delivering the glucocorticoid drug to a target tissue without increasing systemic concentrations of the drug.[0004]Inhaled glucocorticoids are an effective therapy for the control of asth...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/58C07J5/00A61K31/573A61P11/06A61P29/00C07J71/00A61K31/56
CPCC07J5/00C07J71/0031C07J5/0092C07J5/0076A61P11/06A61P29/00
InventorCURRIE, MARK G.JONES, STEVENZEPP, CHARLES M.
OwnerSEPACOR INC